Screening of subclinical P300 event‑related potentials changes in childhood acute lymphoblastic leukemia survivors

  • Authors:
    • Slawomir Kroczka
    • Kinga Kwiecinska
    • Aleksandra Gergont
    • Anna Grela
    • Olga Gorowska
    • Szymon Skoczen
  • View Affiliations

  • Published online on: June 14, 2022     https://doi.org/10.3892/mco.2022.2558
  • Article Number: 125
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Modern treatment of childhood acute lymphoblastic leukemia (ALL) has resulted in a high cure rate; however, it can cause central nervous system toxicity. In the present study, a group of 136 ALL survivors were screened for changes in P300. Therapy was conducted according to a modified New York (NY) protocol (30 patients) and two subsequent revisions of a modified Berlin‑Frankfurt‑Münster (BFM) protocol (32 and 74 patients). The control group consisted of 58 patients. The survivors had significantly prolonged mean latency of P300 (331.31±28.71 vs. 298.14±38.76 msec, P<0.001) and reaction time (439.51±119.86 vs. 380.11±79.94 msec, P=0.002) compared with in the control group. Abnormalities in the endogenous evoked potentials were observed in 36 patients (26.5%). The mean latency time was significantly longer in the treatment groups compared with in the control group (NY: 329.13±28.07 msec, P=0.001; pBFM: 332.97±23.97 msec, P<0.001; BFM95: 331.47±31.05 msec, P<0.001). The reaction time was equally prolonged in both groups. In comparisons between the studied groups and the control group the most significant prolongation was recorded in the NY group (461.8±140.3 vs. 380.1±78.04 msec, P=0.039). Significantly higher frequency of prolonged reaction time in non‑irradiated patients that received BFM95 was also revealed (21.62 vs. 15.85%, P=0.007). In addition, radiotherapy significantly reduced the P300 wave amplitude (mean values: 10.395±5.727 vs. 12.739±6.508 mV, P=0.027). In conclusion, endogenous P300 event‑related potentials may be a useful tool in screening of subclinical cognitive changes in ALL survivors.
View Figures
View References

Related Articles

Journal Cover

August-2022
Volume 17 Issue 2

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kroczka S, Kwiecinska K, Gergont A, Grela A, Gorowska O and Skoczen S: Screening of subclinical P300 event‑related potentials changes in childhood acute lymphoblastic leukemia survivors. Mol Clin Oncol 17: 125, 2022
APA
Kroczka, S., Kwiecinska, K., Gergont, A., Grela, A., Gorowska, O., & Skoczen, S. (2022). Screening of subclinical P300 event‑related potentials changes in childhood acute lymphoblastic leukemia survivors. Molecular and Clinical Oncology, 17, 125. https://doi.org/10.3892/mco.2022.2558
MLA
Kroczka, S., Kwiecinska, K., Gergont, A., Grela, A., Gorowska, O., Skoczen, S."Screening of subclinical P300 event‑related potentials changes in childhood acute lymphoblastic leukemia survivors". Molecular and Clinical Oncology 17.2 (2022): 125.
Chicago
Kroczka, S., Kwiecinska, K., Gergont, A., Grela, A., Gorowska, O., Skoczen, S."Screening of subclinical P300 event‑related potentials changes in childhood acute lymphoblastic leukemia survivors". Molecular and Clinical Oncology 17, no. 2 (2022): 125. https://doi.org/10.3892/mco.2022.2558